Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
| Revenue (Most Recent Fiscal Year) | $673.00M |
| Net Income (Most Recent Fiscal Year) | $-575.00M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.92 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -90.38% |
| Net Margin (Trailing 12 Months) | -91.03% |
| Return on Equity (Trailing 12 Months) | -1024.42% |
| Return on Assets (Trailing 12 Months) | -45.78% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.85 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.14 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.83 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.84 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.11 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 98.49M |
| Free Float | 93.37M |
| Market Capitalization | $3.30B |
| Average Volume (Last 20 Days) | 2.93M |
| Beta (Past 60 Months) | 0.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |